How Ozempic Changed Denmark's Economy — and What Came Next
Ozempic and Wegovy made Novo Nordisk so large that it accounted for one-fifth of Denmark's 2024 employment growth, while pharmaceutical exports helped the economy expand 3.7% — until competition helped cut the 2025 growth forecast to 1.4% and 9,000 layoffs followed.
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.
Ozempic and Wegovy turned their maker, Novo Nordisk, into a company so large that it moved the economic numbers of an entire country. Denmark, a Nordic country of six million people [1], saw its economy expand 3.7% in 2024, boosted by pharmaceutical exports [2], and Novo Nordisk alone accounted for one-fifth of the country’s employment growth that year [1]. By 2023 the company’s market value had grown larger than the domestic economy itself [6], and in 2023 it briefly overtook the luxury group LVMH as Europe’s most valuable company [2].
Then the boom slowed. Competition from Eli Lilly, repeated cuts to the company’s sales forecasts, and U.S. tariffs led Denmark’s economy ministry to cut its 2025 growth forecast to 1.4% from 3% in late August 2025 [1][2]. On September 10, 2025, Novo Nordisk announced it would lay off 9,000 workers [9]. Here is how one drugmaker came to shape a national economy, and what changed when the momentum faded.
Who is Novo Nordisk?
Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. It was founded on December 21, 1923 [6] and is the largest pharmaceutical company in Denmark [6]. Its best-known products today are Ozempic, a diabetes treatment, and Wegovy, a weight-management drug [1][2]. The company also sells insulins and other diabetes medicines, including Levemir, Tresiba, NovoRapid, Victoza and Saxenda [6].
The chairman is Lars Rebien Sørensen, and the president and CEO is Maziar Mike Doustdar [6]. The company’s legal name remains Novo Nordisk A/S, and it is now presented as “Novo” [6]. Its shares trade as NOVO B on Nasdaq Copenhagen, where it is a component of the OMX Copenhagen 25 index [6].
How big did Novo Nordisk get?
Very big, by the standards of a country of six million. In 2023, the company’s market capitalization exceeded the GDP of Denmark’s domestic economy [6]. The scale shows up in its 2025 financials:
| Measure (2025) | Amount |
|---|---|
| Revenue | DKK 309.1 billion [6] |
| Operating income | DKK 127.7 billion [6] |
| Net income | DKK 102.4 billion [6] |
| Total assets | DKK 542.9 billion [6] |
| Total equity | DKK 194.0 billion [6] |
| Employees | 68,794 [6] |
Net sales in 2024 were US$42.121 billion [6]. Even as the share price fell in 2025, earnings stayed strong: in quarterly results published in August 2025, the company reported 67% year-on-year sales growth at constant exchange rates, a figure of DKK 19.53 billion (US$3.03 billion) [2].
How much of Denmark’s economy ran through one company?
A striking amount. Denmark’s growth in 2024 ranked among the highest in Europe, in part driven by Novo Nordisk [1]. Pharmaceuticals contributed 8.1 percentage points of the country’s 10.5% growth in goods exports in 2024 [2].
The dependence ran in both good years and bad. In March 2024, Danske Bank — Denmark’s largest bank — calculated that the country’s 1.8% growth in 2023 would have been completely erased without the pharmaceutical industry’s contribution [5]. At the same time, Danske Bank raised its 2024 Denmark GDP forecast to 2.1% from 1.0%, and its 2025 forecast to 2.0% from 1.6%, citing the drug boom [5].
Forecasters now treat Novo Nordisk’s quarterly results as a leading indicator of Danish GDP — an unusual situation in which one firm’s numbers closely predict the national accounts [4]. The company’s profits have also contributed substantially to Denmark’s budget surplus, which is the largest in the European Union [4].
The stock market tells a similar story. Novo Nordisk makes up a dominant share of the Copenhagen stock index because its market value is huge relative to Denmark’s overall market, which is too small to balance it out [4]. That means pension-fund performance, household investment portfolios and broad market measures all become unusually sensitive to a single share price [4].
What did Novo Nordisk build in Kalundborg?
In November 2023, Novo Nordisk announced it would expand its manufacturing site in Kalundborg, Denmark, with an investment of more than DKK 42 billion — about €5.6 billion, or roughly $6 billion [8][7]. The vast majority of the investment is directed at capacity for making active pharmaceutical ingredients (API), the substance that makes a drug work, though the plan covers the whole value chain from API production to packaging [7].
The new API facility will have a footprint of 170,000 m² (1.82 million ft²) and is designed as a multi-product plant flexible enough to accommodate future processes [7][8]. Construction is scheduled to be finalized gradually from the end of 2025 through 2029 [7][8]. When complete, the expansion is expected to create 800 new jobs — 700 in the API facility and 100 in packaging — with about 3,000 external workers employed during the construction phase [8][7]. The new facility is designed to use roughly 40% less water and 50% less energy than comparable API processes [8].
Kalundborg was already a major industrial site. Novo Nordisk established production there in 1969, and it is now the world’s largest insulin manufacturing plant and the company’s largest site, covering 1.6 million m² and employing 4,400 people [8]. The company had already committed more than DKK 18 billion to Kalundborg between 2000 and 2020, and in 2021 and 2022 announced a further DKK 18 billion for four new production facilities and the rebuilding of three existing ones [8]. The 2023 announcement coincided with the 100th anniversary of the company’s founding in Denmark [8].
Henrik Wulff, Novo Nordisk’s executive vice president for Product Supply, Quality & IT, said the investment “confirms the importance of utilizing our existing sites, including in Denmark, as cornerstones for not only the growth we see but also to expand as fast as possible” [7]. Beyond Kalundborg, the company is awaiting approvals for a new production site on Funen, Denmark [7][8], and operates its Bagsværd headquarters (inaugurated in 2014), a NovoSeven biopharmaceutical plant in Hillerød, and a global raw-material warehouse in Hillerød opened in 2018 [8].
Why did economists worry about one company being so big?
Because other countries have been through it. The comparison economists reach for is Finland during the Nokia era, when that country’s exports, stock market and employment all became closely tied to one firm — and Finland faced a sharp fall in exports and a painful adjustment when Nokia’s market share declined [4].
There was also a currency channel. Allianz Research reported that expectations of future GLP-1 export volumes contributed to appreciation pressure on the Danish krone [4]. A stronger krone lowers import costs for households but reduces the competitiveness of Denmark’s other exports [4]. That is a mild version of the dynamic often seen in natural-resource economies, where a booming export sector strengthens the currency and shifts resources away from other tradable industries [4].
Policymakers had few good options. Cutting Novo Nordisk’s weight in the stock index would hurt market liquidity, and pushing pension money into smaller firms could distort how capital is allocated [4]. Denmark remains structurally diversified — it is home to large companies like the shipping group Maersk, brewer Carlsberg, toymaker Lego and wind turbine maker Vestas [1], and it has an export-oriented economy helped by a large savings surplus and solid public finances [1]. But the headline economic numbers increasingly reflected one firm’s outcomes, even if the economy’s makeup stayed varied [4].
What went wrong for Novo Nordisk in 2025?
Competition and price pressure. In August 2025, Novo Nordisk cut its full-year sales and operating profit forecasts for the second time that year, as it struggled to convince investors it could stay competitive in the obesity drug market against its U.S. rival Eli Lilly [1].
The share price told the story: down more than 10% in 2024 and down more than 40% in 2025 year-to-date as of late August [2]. S&P Global notes that Eli Lilly may overtake Novo Nordisk in the weight-loss drug market on the strength of a faster-moving research pipeline and aggressive investment [4], and analysts suggest that shift could occur within the next two to four years, depending on regulatory approvals and production capacity [4]. The Danish economy ministry said generic medicines are also squeezing the company’s sales opportunities in the U.S. [2], and in its August 2025 results the company said it would double down on direct-to-consumer sales in its battle with copycat compounders and U.S. pressure for lower drug prices [2].
How did Denmark change its official forecast?
In late August 2025, Denmark’s economy ministry cut its 2025 GDP growth forecast to 1.4% from 3% [1][2].
| Forecast | Before | Late August 2025 update |
|---|---|---|
| 2025 GDP growth | 3% [1][2] | 1.4% [1][2] |
| 2025 export growth | 4.3% (May forecast) [1] | 0.9% [1] |
| 2026 GDP growth | 1.4% [1][2] | 2.1% [1][2] |
The ministry cited several reasons: weaker prospects for Novo Nordisk, U.S. tariffs on Danish goods, weaker growth in the first quarter of 2025, and a statistical revision showing that real GDP grew less in 2021–2024 than previously calculated [1][2]. “The pharmaceutical industry is increasingly challenged by competition in the markets for weight loss products, which has dampened growth expectations in the industry,” the ministry said in a statement [1].
The export numbers show the swing. Pharmaceuticals are now expected to contribute just 1.3 percentage points to Denmark’s goods export growth in 2025, down from 8.1 percentage points in 2024, and total goods export growth is projected at 2.7%, down from 10.5% the previous year [2]. The U.S. is Denmark’s biggest export market, and exports to the U.S. fell significantly in the first half of 2025 after a spike in late 2024 that reflected inventory build-up [1][2].
The ministry also raised its 2026 GDP growth forecast to 2.1% from 1.4%, on expectations of higher private and public consumption [1][2]. It stressed that the economy remains strong overall, with high employment and inflation expected below 2% on an annual basis [2]. A Novo Nordisk spokesperson declined to comment on the forecast change [1].
How many jobs did Novo Nordisk cut?
On September 10, 2025, Novo Nordisk announced layoffs of 9,000 workers in a major restructuring [9]. The company’s new CEO framed the cuts as a way to make the company more agile as it reels from competition in the obesity market and a declining stock price [9].
The cuts came after a period of rapid hiring. Novo Nordisk employed around 34,000 people in Denmark as of August 2025, after almost doubling its total workforce over the previous five years [1].
Who actually owns Novo Nordisk?
A foundation, through a holding company. Novo Nordisk is controlled by Novo Holdings A/S, which is wholly owned by the Novo Nordisk Foundation [6]. Novo Holdings holds approximately 28% of the shares and about 77% of the voting shares [6]. The company’s shares are listed as NOVO B on Nasdaq Copenhagen [6].
Where do things stand now?
Denmark’s economy ministry expects growth of 2.1% in 2026, up from its earlier 1.4% forecast, on expectations of higher private and public consumption [1][2]. The Kalundborg construction program is still scheduled to run through 2029 [7][8], and the company’s earnings remained robust even as its share price fell [2]. The ministry’s view as of August 2025 was that the Danish economy is still strong overall, with high employment and inflation expected below 2% [2].
What does all this mean for someone in the U.S. taking Ozempic?
Not much clinically. The Kalundborg build-out is about manufacturing capacity — making enough API to supply current and future products [7][8]. It says nothing about whether a GLP-1 medicine is right for any individual. Decisions about starting, stopping or switching these drugs belong with a licensed healthcare provider, and Denmark’s macroeconomic fortunes are not a signal about a medicine’s suitability for a particular patient.
Sources
- Global Banking & Finance Review. Novo Nordisk woes prompt Denmark to slash country’s 2025 growth forecast. August 28, 2025.
- CNBC. Denmark slashes 2025 growth forecast amid Novo Nordisk slowdown. August 29, 2025.
- The New York Times. News article on Novo Nordisk and the Danish economy.
- Columbia Economic Review. The Novo Nordisk Economy: Denmark’s Growing Dependence on a Single Pharma Giant.
- Fortune. Novo Nordisk’s Wegovy and Ozempic boom saved Denmark’s GDP from a no-growth 2023—and will help double its expected growth this year. March 5, 2024.
- Wikipedia. Novo (company).
- CHEManager. Novo Nordisk to Invest €5.6 Billion in Expansion of API Production in Denmark.
- Pharmaceutical Technology. Novo Nordisk’s API Manufacturing Facility, Kalundborg, Denmark.
- BioPharma Dive. Novo Nordisk to lay off 9,000 workers in major restructuring.
- Reuters. Inside Novo Nordisk’s ‘Club 5,000’ as Danish staff cuts gain pace. October 15, 2025.
- Novo Holdings. Novo Holdings announces 2025 Annual Results. March 12, 2026.
- Novo Nordisk Fonden. Ownership.
- Novo Nordisk. Five-year overview. Novo Nordisk Annual Report 2025.
- Financial Post. News article on Novo Nordisk layoffs and Denmark’s economic anxieties.
- Bloomberg. Danish Economy to Outpace Nordics Despite Novo Woes, Danske Says. March 4, 2026.
- Reuters. Novo Nordisk briefly overtakes LVMH as Europe’s most valuable company. September 1, 2023.
- GlobeNewswire. Novo Nordisk enters next chapter to bring better health to more people supported by Novo rebrand and updated corporate culture. September 14, 2026.
Frequently asked questions
Is Ozempic made in Denmark, and where exactly?
Novo Nordisk is headquartered in Bagsværd, Denmark, and its biggest manufacturing site is Kalundborg, established in 1969 — the world's largest insulin manufacturing plant, covering 1.6 million m² with 4,400 employees. The site makes all of the company's diabetes API, along with some biopharmaceutical and obesity-treatment products.
What share of Denmark's economy is Novo Nordisk?
There is no single percentage, but the scale is unusual: the company's market capitalization exceeded the GDP of Denmark's domestic economy in 2023, it accounted for one-fifth of Denmark's employment growth in 2024, and it makes up a dominant share of the Copenhagen stock index. Its profits also contributed substantially to Denmark's budget surplus, the largest in the EU.
Why did Denmark cut its growth forecast in 2025?
In August 2025 the economy ministry cut its 2025 GDP growth forecast to 1.4% from 3%, citing weaker prospects for Novo Nordisk, U.S. tariffs on Danish goods, weaker first-quarter growth, and a statistical revision showing 2021–2024 growth was lower than previously calculated. Export growth for 2025 was cut to 0.9% from the May forecast of 4.3%.
How many people does Novo Nordisk employ in Denmark?
Around 34,000 people in Denmark as of August 2025, after the company almost doubled its total workforce over the previous five years. Worldwide, the company reported 68,794 employees in 2025.
How many jobs did Novo Nordisk cut, and when?
On September 10, 2025, Novo Nordisk announced 9,000 layoffs worldwide in a major restructuring. The new CEO said the cuts would make the company more agile amid competition in the obesity market and a declining stock price. The cuts followed a period of rapid hiring: the company employed around 34,000 people in Denmark as of August 2025.
Who actually owns Novo Nordisk?
Novo Nordisk is controlled by Novo Holdings A/S, which is wholly owned by the Novo Nordisk Foundation, a Danish foundation. Novo Holdings holds about 28% of the shares and roughly 77% of the voting shares. The company's shares are listed as NOVO B on Nasdaq Copenhagen.
Is Denmark's situation like Finland's with Nokia?
Economists draw that comparison. During the Nokia era, Finland's exports, stock market and employment became closely tied to one firm, and when Nokia's market share declined, Finland faced a sharp fall in exports and significant economic adjustment. Analysts warn Denmark risks a similar dynamic, though its economy remains structurally diversified.
Did Novo Nordisk's stock decline hurt ordinary Danes' pensions?
It raised the risk. Because Novo Nordisk makes up a dominant share of the Copenhagen stock index and Denmark's market is too small to balance it out, pension-fund performance, household portfolios and broad market measures become unusually sensitive to one company's share price.
This article summarizes FDA labeling, published research and company information current as of October 18, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.